Intellipharmaceutics price target raised to $9 from $7 at Maxim

theflyonthewall.com

Maxim raised its price target for Intellipharmaceutics to $9 after the FDA approved the company’s generic version of Focalin. The firm keeps a Buy rating on the stock.

View Comments